LAVA Therapeutics
- Country
- 🇳🇱Netherlands
- Ownership
- Public
- Established
- 2016-01-01
- Employees
- 35
- Market Cap
- $48.6M
- Introduction
LAVA Therapeutics NV is an immuno-oncology company, which engages in the proprietary Gammabody platform to develop a portfolio of bispecific gamma delta T cell engagers for the potential treatment of solid tumors and hematological malignancies. The company was founded by Erik van den Berg in 2016 and is headquartered in Utrecht, the Netherlands.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
Trial of LAVA-1207 in Patients with Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2022-05-11
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Lava Therapeutics
- Target Recruit Count
- 180
- Registration Number
- NCT05369000
- Locations
- 🇺🇸
UCSF Medical Center at Parnassus, San Francisco, California, United States
🇺🇸M Health Fairview University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸Washington University School of Medicine in St. Louis, Saint Louis, Missouri, United States
Trial of LAVA-051 in Patients with Relapsed/refractory CLL, MM, or AML
- Conditions
- Chronic Lymphocytic LeukemiaMultiple MyelomaAcute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-05-14
- Last Posted Date
- 2025-01-27
- Lead Sponsor
- Lava Therapeutics
- Target Recruit Count
- 16
- Registration Number
- NCT04887259
- Locations
- 🇺🇸
Emory Winship Cancer Institute, Atlanta, Georgia, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸Levine Cancer Institute, Atrium Health, Charlotte, North Carolina, United States
News
Commit Biologics Forms Scientific Advisory Board to Advance Complement-Based Cancer and Autoimmune Therapies
Commit Biologics has established a Scientific Advisory Board co-chaired by antibody expert Janine Schuurman and CEO Mikkel Wandahl Pedersen to guide development of its BiCE™ complement activation platform.
LAVA Therapeutics Reports Q1 2025 Results While Restructuring Operations and Advancing Clinical Trials
• LAVA Therapeutics is implementing significant restructuring, including a 30% workforce reduction and closure of Netherlands operations, while evaluating strategic alternatives to maximize shareholder value. • The company continues to advance its LAVA-1266 Phase 1 trial for CD123+ hematological malignancies, alongside partnered programs with Johnson & Johnson and Pfizer that are also in Phase 1 clinical trials. • With $66.6 million in cash and investments as of March 31, 2025, LAVA expects to fund operations into 2027 despite reporting a net loss of $3.5 million for Q1 2025.
LAVA Therapeutics Doses First Patient in Phase 1 Trial of LAVA-1266 for Hematological Cancers
• LAVA Therapeutics has dosed the first patient in a Phase 1 trial of LAVA-1266, a bispecific Gammabody® targeting CD123 for hematological cancers. • The first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of LAVA-1266 in AML and MDS patients. • LAVA-1266 is designed to lyse CD123+ tumor cells with high potency and a wide therapeutic window, potentially overcoming limitations of previous CD123-targeted therapies. • Initial Phase 1 data read-out from the dose escalation study is expected by the end of 2025, marking a key milestone for the company's Gammabody® platform.